Recent Phase 3 trial results have validated a new class of oral treatments that could transform how autoimmune diseases are treated, moving away from inconvenient injections to simple pills.
These oral therapies could capture significant market share from the injectable biologics that currently dominate autoimmune treatment, representing a multi-billion pound opportunity.
Success in TYK2 inhibitor trials reduces development risk for other companies in this space, potentially accelerating approvals and driving sector-wide growth.
This basket's total market capitalisation is 1,994,443.68133, with its weight heavily concentrated in a limited number of large-cap stocks. That concentration tends to anchor performance, making the basket less sensitive to small-cap volatility.
BMY: $110.79B
PFE: $144.59B
AMGN: $177.79B
Recent breakthrough clinical trial results have validated selective TYK2 inhibitors as a promising new class of oral treatments for autoimmune diseases. This represents a potential shift away from injectable biologics that have dominated the market, offering patients more convenient treatment options with strong efficacy profiles.
This group focuses on pharmaceutical and biotechnology companies developing next-generation oral autoimmune therapies, particularly for psoriasis and related conditions. These companies range from established pharmaceutical giants to innovative clinical-stage biotechs, all working on treatments that could transform patient care in immunology.
Each company has been carefully selected for their involvement in TYK2 inhibitors, oral autoimmune treatments, or related therapeutic areas. The selection includes both companies with approved treatments and those with promising clinical pipelines, positioned to benefit from the growing validation of this therapeutic approach.
Alumis's breakthrough trial results for its oral psoriasis drug have highlighted the massive potential of advanced autoimmune therapies. This theme focuses on the pharmaceutical companies pioneering next-generation oral treatments, particularly selective TYK2 inhibitors, which represent a new frontier in convenient and effective patient care.
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
1์ 7 ๊ฒ์
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+9.43%
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 9.43% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 15๊ฐ ์ค 13๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
